Compare TNXP & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | CMT |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | 1239 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.7M | 186.0M |
| IPO Year | 2008 | 1996 |
| Metric | TNXP | CMT |
|---|---|---|
| Price | $13.65 | $22.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 419.1K | 27.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | $13,107,000.00 | ★ $284,290,000.00 |
| Revenue This Year | $558.11 | $4.58 |
| Revenue Next Year | $38.29 | $6.04 |
| P/E Ratio | ★ N/A | $17.19 |
| Revenue Growth | ★ 29.85 | 5.49 |
| 52 Week Low | $11.60 | $13.99 |
| 52 Week High | $69.65 | $22.97 |
| Indicator | TNXP | CMT |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 61.51 |
| Support Level | $13.32 | $17.42 |
| Resistance Level | $20.36 | N/A |
| Average True Range (ATR) | 1.18 | 1.00 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 37.93 | 82.11 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.